- Home
- RIGL vs UROY Comparison
RIGL vs UROY Comparison
Compare RIGL & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | UROY |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 601.8M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | UROY |
|---|---|---|
| Price | $29.44 | $3.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $45.67 | $4.50 |
| AVG Volume (30 Days) | 261.8K | ★ 2.2M |
| Earning Date | 05-05-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 19.48 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $279.20 |
| Revenue Next Year | $12.75 | N/A |
| P/E Ratio | ★ $1.57 | $1,584.46 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $16.05 | $1.63 |
| 52 Week High | $52.24 | $5.52 |
Technical Indicators
Market Signals| Indicator | RIGL | UROY |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 46.61 |
| Support Level | $28.08 | $3.46 |
| Resistance Level | $30.59 | $4.03 |
| Average True Range (ATR) | 1.10 | 0.19 |
| MACD | 0.74 | 0.04 |
| Stochastic Oscillator | 77.44 | 53.69 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.